Crossmark

Based on disulfidptosis, unveiling the prognostic and immunological signatures of Asian hepatocellular carcinoma and identifying the potential therapeutic target ZNF337-AS1

Crossref DOI link: https://doi.org/10.1007/s12672-025-02325-5

Published Online: 2025-04-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shen, Duo

Sha, Ling

Yang, Ling

Gu, Xuefeng https://orcid.org/0000-0002-6198-2568
Funding

Funding for this research was provided by:

Project of Modern Hospital Management and Development Institute, Nanjing University, Aid project of Nanjing Drum Tower Hospital Health, Education & Research Foundation (NDYG2021046)
License Information

Text and Data Mining valid from 2025-04-17

Version of Record valid from 2025-04-17
More Information

Article History

Received: 28 September 2024

Accepted: 7 April 2025

First Online: 17 April 2025

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. The Ethics Committee of the jurong hospital affiliated to jiangsu university (zhenjiang, China) approved the present study (approval no. JRSRMYY-2023–042) of tumor research. Each patient provided written informed consent for participation.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below